Dive into the archives.
- RegeneRx’s Tβ4 Significantly Improves Functional Recovery in MS Animal Model
BETHESDA, Md.–REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) announced today that researchers at the Henry Ford Health System in Detroit, Michigan, demonstrated for the first time that Tβ4 treatment of EAE (experimental autoimmune encephalomyelitis – an [...]
- Novartis says FTY720 reduces relapses
ZURICH, Sept 30 (Reuters) – Swiss drugmaker Novartis AG said on Wednesday its FTY720 oral drug to treat multiple sclerosis reduced both relapses and disability progression.
Initial results from the two-year Phase III study show that oral FTY720 was significantly superior to placebo in reducing both relapses and disability progression in patients with relapsing-remitting multiple sclerosis, [...]
- Merck Discontinues Ph 2 Trial of Atacicept in MS
September 28, 2009
by Matthew Dennis
Merck KGaA has decided to discontinue Phase II clinical trials of atacicept for the treatment of multiple sclerosis based on a recommendation from a data monitoring panel, according to ZymoGenetics. The panel observed an increase in disease activity in patients receiving the drug compared to those administered placebo in one study
Merck [...]
- Don’t Hold Your Breath For Generic Avonex
September 16, 2009 — 11:47am ET | By George Miller
Biogen Idec has succeeded in extending patent protection for its multiple sclerosis drug Avonex to 2026, some 13 years beyond the original patent-expiration date. The IP sleight of hand comes in the form of a newly issued method-of-use patent, which also covers Avonex treatment of multiple [...]
- Biogen Reports 2 More Cases of PML with Tysabri
By THOMAS GRYTA
Two more cases of a rare brain infection have emerged in users of the multiple-sclerosis drug Tysabri, sold by Biogen Idec Inc. and Elan PLC, the first such incidences since Biogen stopped updating investors of the situation in July.
At that time, Biogen had confirmed 11 cases of progressive multifocal leukoencephalopathy, or PML, since [...]
- MS and Diet: What do You Think?
Excerpt from Chapter 1: What is MS?
A safe conclusion is that MS is one or, possibly, many diseases in which there is destruction of the myelin sheath surrounding the nerves causing a disruption of the electrical impulses. Along with this there is a second disease process of axonal destruction under both white and gray matter [...]
- Hot off the ECTRIMS Press…Alemtuzumab Shows Lasting Benefits in RRMS
(RTTNews) - Friday, biotechnology company Genzyme Corp. said that four-year follow-up data from its completed Phase [...]
- Hot off the ECTRIMS Press…Sanofi Oral is Promising
LONDON, Sept 11 (Reuters) – Patients given an experimental multiple sclerosis tablet from Sanofi-Aventis showed a significant improvement compared to those on placebo in a mid-stage test, researchers said on Friday.
Teriflunomide, which was used as an add-on therapy to interferon beta in the Phase II clinical trial, is one of a number of MS drugs [...]
- Hot off the ECTRIMS Press…Fewer Injection Site Reactions with Avonex
CAMBRIDGE, MA – Sept. 11, 2009 – Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis (MS) patients taking AVONEX (interferon beta-1a IM) reported significantly fewer injection site reactions (ISRs) compared to patients on Betaferon (interferon beta-1b), Copaxone (glatiramer Acetate) or Rebif (interferon beta-1a). [...]
- Hot off the ECTRIMS Press…Cladribine Reduces Disease Activity in a Big Way
Darmstadt, Germany, September 11, 2009 – Merck KGaA announced today new data from a post-hoc analysis of the two-year (96-week) placebo-controlled CLARITY(1) Phase III trial using a short-course of Cladribine Tablets (the proprietary investigational oral formulation of cladribine) to treat patients with relapsing-remitting multiple sclerosis (MS). The data from this post-hoc analysis of the CLARITY [...]
